BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
1. BioNTech acquires CureVac in an all-stock deal valued at $1.25 billion. 2. CureVac shareholders will own 4%-6% of BioNTech post-acquisition. 3. BioNTech strengthens mRNA cancer immunotherapy capabilities with this transaction. 4. The deal may enhance BioNTech's oncology strategy, including BNT327. 5. BioNTech has significant cash reserves of €15.9 billion.